Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.
Shenai, Shubhada; Ronacher, Katharina; Malherbe, Stefanus; Stanley, Kim; Kriel, Magdalena; Winter, Jill; Peppard, Thomas; Barry, Charles E; Wang, Jing; Dodd, Lori E; Via, Laura E; Barry, Clifton E; Walzl, Gerhard; Alland, David.
; 11(8): e0160062, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27508390
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
The immune response in tuberculosis.
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
Baciloscopia positiva persistente en fase avanzada de la terapia anti-tuberculosa: no siempre indica fracaso del tratamiento.
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens.